Neurotech International Limited, together with its subsidiaries, engages in the research, design, development, and manufacture of medical devices and solutions in Australia.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.055|
|52 Week High||AU$0.021|
|52 Week Low||AU$0.084|
|1 Month Change||25.00%|
|3 Month Change||5.77%|
|1 Year Change||120.00%|
|3 Year Change||-31.25%|
|5 Year Change||n/a|
|Change since IPO||-80.70%|
Recent News & Updates
Neurotech International (ASX:NTI) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Neurotech...
|NTI||AU Medical Equipment||AU Market|
Return vs Industry: NTI exceeded the Australian Medical Equipment industry which returned -7.4% over the past year.
Return vs Market: NTI exceeded the Australian Market which returned 24.4% over the past year.
Stable Share Price: NTI is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: NTI's weekly volatility (12%) has been stable over the past year.
About the Company
|2016||n/a||Peter James Griffiths||https://www.neurotechinternational.com|
Neurotech International Limited, together with its subsidiaries, engages in the research, design, development, and manufacture of medical devices and solutions in Australia. The company is focused on developing neurostimulation and neurodiagnostic solutions to be delivered through the Mente platform, a platform technology to enable medical practitioners to remotely monitor and play role in home-based therapies. Its product includes Mente Autism for the diagnosis and treatment of autism.
Neurotech International Fundamentals Summary
|NTI fundamental statistics|
Is NTI overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|NTI income statement (TTM)|
|Cost of Revenue||-AU$20.34k|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.011|
|Net Profit Margin||-3,294.65%|
How did NTI perform over the long term?See historical performance and comparison
Is Neurotech International undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate NTI's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate NTI's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: NTI is unprofitable, so we can't compare its PE Ratio to the Australian Medical Equipment industry average.
PE vs Market: NTI is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NTI's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NTI is overvalued based on its PB Ratio (9.9x) compared to the AU Medical Equipment industry average (4.5x).
How is Neurotech International forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Neurotech International has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Neurotech International performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NTI is currently unprofitable.
Growing Profit Margin: NTI is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: NTI is unprofitable, and losses have increased over the past 5 years at a rate of 6.5% per year.
Accelerating Growth: Unable to compare NTI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NTI is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (74.9%).
Return on Equity
High ROE: NTI has a negative Return on Equity (-192.43%), as it is currently unprofitable.
How is Neurotech International's financial position?
Financial Position Analysis
Short Term Liabilities: NTI's short term assets (A$5.0M) exceed its short term liabilities (A$349.4K).
Long Term Liabilities: NTI's short term assets (A$5.0M) exceed its long term liabilities (A$795.0K).
Debt to Equity History and Analysis
Debt Level: NTI is debt free.
Reducing Debt: NTI has no debt compared to 5 years ago when its debt to equity ratio was 61.8%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NTI has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: NTI has sufficient cash runway for 1.2 years if free cash flow continues to grow at historical rates of 17.5% each year.
What is Neurotech International current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NTI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NTI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NTI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NTI's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NTI's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Peter James Griffiths (57 yo)
Mr. Peter James Lawrence Griffiths, B.Sc. (Hons), has been the Chief Executive Officer of AAT Research Ltd at Neurotech International Limited since October 2020 and served as its Chief Executive Officer an...
CEO Compensation Analysis
Compensation vs Market: Peter James's total compensation ($USD81.73K) is below average for companies of similar size in the Australian market ($USD301.38K).
Compensation vs Earnings: Peter James's compensation has been consistent with company performance over the past year.
Experienced Management: NTI's management team is considered experienced (2.5 years average tenure).
Experienced Board: NTI's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 79.3%.
Neurotech International Limited's employee growth, exchange listings and data sources
- Name: Neurotech International Limited
- Ticker: NTI
- Exchange: ASX
- Founded: 2016
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: AU$36.235m
- Shares outstanding: 696.82m
- Website: https://www.neurotechinternational.com
- Neurotech International Limited
- 145 Stirling Highway
- Suite 5 CPC
- Western Australia
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/26 07:02|
|End of Day Share Price||2021/10/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.